- Report
- February 2024
- 70 Pages
Brazil
From €4241EUR$4,750USD£3,710GBP
- Report
- February 2024
- 70 Pages
Germany
From €4241EUR$4,750USD£3,710GBP
- Report
- February 2024
- 70 Pages
Canada
From €4241EUR$4,750USD£3,710GBP
- Report
- February 2024
- 70 Pages
Italy
From €4241EUR$4,750USD£3,710GBP
- Report
- February 2024
- 70 Pages
Japan
From €4241EUR$4,750USD£3,710GBP
- Report
- August 2023
- 150 Pages
North America
From €4241EUR$4,750USD£3,710GBP
- Report
- August 2023
- 70 Pages
Africa, Middle East
From €4241EUR$4,750USD£3,710GBP
- Report
- August 2023
- 70 Pages
South Korea
From €4241EUR$4,750USD£3,710GBP
- Report
- August 2023
- 70 Pages
Spain
From €4241EUR$4,750USD£3,710GBP
- Report
- June 2025
- 250 Pages
Canada
From €2490EUR$2,789USD£2,178GBP
- Report
- December 2023
- 142 Pages
Brazil
From €2232EUR$2,500USD£1,953GBP
- Report
- May 2024
- 145 Pages
Global
From €3526EUR$3,950USD£3,085GBP
- Report
- February 2022
- 195 Pages
Global
From €3214EUR$3,600USD£2,812GBP
- Report
- October 2020
- 133 Pages
Global
From €13387EUR$14,995USD£11,712GBP
- Report
- May 2023
- 160 Pages
Global
From €4418EUR$4,949USD£3,865GBP
- Report
- May 2023
- 147 Pages
Global
From €4418EUR$4,949USD£3,865GBP
- Report
- March 2025
- 50 Pages
Kenya
From €536EUR$600USD£469GBP
- Report
- March 2025
- 50 Pages
Nigeria
From €536EUR$600USD£469GBP
- Report
- March 2025
- 50 Pages
Egypt
From €536EUR$600USD£469GBP
From €536EUR$600USD£469GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more